Genetic Engineering Market

Increased incidence of genetic disorders is driving the market growth

Market CAGR for genetic engineering is driven by the rising number of genetic disorders. Market expansion is fueled by the growing application of genome engineering in treating chronic conditions. The use of transcriptome, genomic, or other multi-omics cells in the early, precise, and quick treatment of infectious and chronic diseases propels market expansion. The development of CRISPR gene editing technology, the advancement of gene therapy, and funding from the public and private sectors are further factors driving the market's growth.

Aside from that, the continuous prevalence of chronic and infectious diseases, including HIV/AIDS, malaria, hepatitis, TB, and others, has led to an increase in the use of genetic engineering in treating these illnesses in recent years. This element promotes market expansion as well.

Governments worldwide have recently made large investments in the field of genomics, which has greatly aided in the advancement of novel genetic engineering technologies. Additionally, the availability of government financing has made it possible for government and university institutions to do extensive research on genome engineering. For instance, the Ministry of Innovation, Science, and Industry (Science) announced in March 2020 that Genome Canada would receive USD 15 million to support 11 genomic research initiatives in health, agriculture, and the environment. Provincial governments, companies, and research partners will invest USD 29.7 million to assist these research programs.

The projects cover ovarian and cervical cancer research. There has been a tremendous increase in genomics research initiatives due to large government investments in the field. In turn, during the forecast period, this is anticipated to assist the expansion of the genetic engineering market. Thus, driving the genetic engineering market revenue.

The Global Genetic Engineering Market Industry is projected to experience substantial growth over the coming years. The market is valued at approximately 1.68 USD Billion in 2024 and is expected to reach 13.7 USD Billion by 2035. This growth trajectory indicates a compound annual growth rate of 21.0% from 2025 to 2035. Such projections highlight the increasing adoption of genetic engineering technologies across various sectors, including agriculture and medicine. The anticipated expansion of the market underscores the potential for genetic engineering to address global challenges, such as food security and health care advancements.

The Global Genetic Engineering Market Industry benefits from favorable regulatory frameworks that support the development and commercialization of genetically engineered products. Governments worldwide are recognizing the potential of biotechnology to address pressing global challenges, such as food security and environmental sustainability. For example, regulatory agencies are streamlining approval processes for genetically modified organisms, which encourages innovation and investment in the sector. This supportive environment is likely to enhance market growth, as evidenced by the projected increase in market value from 1.68 USD Billion in 2024 to 13.7 USD Billion by 2035, reflecting the growing acceptance of biotechnology in agriculture.

Innovations in gene editing technologies, such as CRISPR-Cas9, play a pivotal role in shaping the Global Genetic Engineering Market Industry. These advancements enable precise modifications to DNA, facilitating the development of crops with desirable traits. The efficiency and accuracy of these technologies have led to their widespread adoption in research and commercial applications. As a result, the market is likely to witness a compound annual growth rate of 21.0% from 2025 to 2035. This growth is indicative of the increasing investment in research and development, as well as the potential for gene editing to revolutionize agriculture and medicine.

The Global Genetic Engineering Market Industry is increasingly influenced by the growing awareness of sustainable agricultural practices. Consumers and farmers are becoming more conscious of the environmental impact of traditional farming methods, leading to a shift towards biotechnology solutions that promote sustainability. Genetically modified crops can reduce the need for chemical pesticides and fertilizers, thereby minimizing environmental harm. This trend aligns with global efforts to achieve sustainable development goals, potentially driving market growth. The market's value is expected to rise from 1.68 USD Billion in 2024 to 13.7 USD Billion by 2035, reflecting the increasing demand for sustainable agricultural practices.

The Global Genetic Engineering Market Industry experiences a surge in demand for genetically modified crops, driven by the need for increased agricultural productivity. As the global population continues to grow, the pressure on food supply intensifies. Genetically modified crops offer enhanced resistance to pests and diseases, which can lead to higher yields. For instance, in 2024, the market is valued at approximately 1.68 USD Billion, reflecting the increasing adoption of biotechnology in agriculture. This trend is expected to continue as farmers seek sustainable solutions to meet food security challenges, potentially contributing to the projected growth of the market to 13.7 USD Billion by 2035.

Investment in agricultural biotechnology is a significant driver of the Global Genetic Engineering Market Industry. Stakeholders, including governments, private companies, and research institutions, are channeling resources into developing innovative solutions for crop improvement. This influx of capital supports research initiatives and the commercialization of genetically modified crops. As a result, the market is poised for substantial growth, with projections indicating a rise from 1.68 USD Billion in 2024 to 13.7 USD Billion by 2035. The anticipated compound annual growth rate of 21.0% from 2025 to 2035 underscores the potential for biotechnology to transform agricultural practices and enhance food production.

The US-based bioscience company has submitted an RSR application to USDA-APHIS Biotechnology Regulatory Services (BRS) following the SECURE Rule for its exclusive elite camelina varieties, which contain genes that allow the plant to generate the eicosapentaenoic acid (EPA) part of omega-3 oil. New plants with the same genetic change would not be controlled in the same way after it is determined that a specific plant created through genetic engineering does not require regulation.

To start ramping up its seed stock for future plantings and to start producing oil for use in expanding its business operations, Yield10 began growing omega-3 (EPA) Camelina at an acre-scale in the US in the spring of 2023.

By region, the study provides market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American genetic engineering market area will dominate this market. The primary factors driving the market's rise in North America consist of the advancement of gene therapy, an increase in the use of GM crops, and an increase in the availability of research grants and financing in the US. Due to several government initiatives and the escalation of genomics research and development (via GAPP) in the nation, the Canadian market is anticipated to expand in the future.

Further, the major countries studied in the market report are US, Canada, France, German, Italy, UK, Spain, Japan, China, Australia, India, South Korea, and Brazil.

Figure 2: GENETIC ENGINEERING MARKET SHARE BY REGION 2022 (USD Billion)

Source: Secondary Research, Primary Research, Market Research Future Database and Analyst Review

Europe’s genetic engineering market accounts for the second-largest market share. Growing government and private funding, expanded genomic projects, and increased investment will fuel market expansion. Consumer genomics will undoubtedly favor the growth of the European genetic engineering sector in the coming years. Further, the German genetic engineering market held the largest market share, and the UK genetic engineering market was the rapidly growing market in the European region.

The Asia-Pacific Genetic Engineering Market is expected to grow at the fastest CAGR from 2023 to 2032. China is the largest market for genetic engineering technologies in the Asia Pacific due to government initiatives supporting the growth of genomic research. Due to the Chinese government's increased emphasis on precision medicine and the existence of significant players like BGI and Hebei Senlang Biotechnology, the region's genetic engineering market is poised for expansion. Moreover, China’s genetic engineering market held the largest market share, and the Indian genetic engineering market was the rapidly growing market in the Asia-Pacific region.

Leading market players are largely investing in research and development to expand their product lines, which will help the genetic engineering market, grow even more. The launch of new products, larger-scale mergers and acquisitions, contractual agreements, and collaboration with other organizations are significant market developments in which market participants engage to increase their global presence. The genetic engineering industry must provide affordable products to expand and thrive in a more competitive and challenging market environment.

One of the major business strategies manufacturers use in the global genetic engineering industry to increase market sector and benefit customers is local manufacturing to lower operational costs. In recent years, the genetic engineering industry has stipulated some of the most important medicinal benefits.  Major players in the genetic engineering industry, including Precision Biosciences, Intellia Therapeutics Inc., Merck KGaA, Sangamo, Thermo Fisher Scientific Inc, and others, are funding operations for research and development to boost market demand.

Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical business focused on altering the daily lives of patients suffering from devastating diseases by developing next-generation, genome-edited cell therapies based on its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA). The company operates and manages its operations as a single reportable operating segment, which involves the development of an allogeneic CAR-T and CAR-NK cell therapy pipeline. In May 2020, Caribou Science engaged in a commercial and clinical license arrangement with MaxCyte. The agreement sought exclusive use of MaxCyte's flow electroporation technology and the ExPERT platform.

Caribou's gene-edited allogeneic T-cell treatment programs progressed due to this strategy, as were its business relationships in the genetic engineering sector.

Thermo Fisher Scientific Inc. is an American manufacturer and distributor of scientific instruments, reagents, consumables, and software services. Thermo Fisher, headquartered in Waltham, Massachusetts, was founded in 2006 by merging Thermo Electron and Fisher Scientific.  Scientific instruments, laboratory equipment, diagnostics consumables, and life science reagents are all available from Thermo Fisher Scientific. In April 2022, Thermo Fisher Scientific released a new Gibco CTS TrueCut Cas9 Protein, as high-quality support material and documents are vital as genome editing researchers progress from fundamental research to therapeutic settings.

It is a viable approach for CAR T-cell therapy research employing CRISPR-Cas9 genome editing since it routinely achieves greater than 90% efficacy in human primary T-cells and high editing effectiveness in all cell lines tested.